Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

• Status: Not yet recruiting
• Trial end date: 2029-09-01

Summary

This is a multicentre open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria (control arm) or by a transcriptomic treatment specific stratification signature or TSS (test arm).

• Phase: Phase 3

Details

• Lead Sponsor: John Neoptolemos
• Collaborators: Deutsches Krebsforschungszentrum (DKFZ); Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Institute of Medical Biometry and Informatics; Molecular Health GmbH; Nationales Centrum für Tumorerkrankungen
• Treatments: Capecitabine; Fluorouracil; Folic Acid; Gemcitabine; Irinotecan; Leucovorin; Levoleucovorin; Oxaliplatin